Palifermin

NIOSH table

Table 2 Non-antineoplastic — eligible for a documented Assessment of Risk.

AHFS classification

84:16 cell stimulants and proliferants

Biologic

May sit outside NIOSH’s evaluation scope (CBER rather than CDER). Verify scope, then assess.

Screen the current package insert

This page reports this drug’s status on the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024. It is not a hazard determination and not a handling instruction. Your facility makes its own Assessment of Risk under USP <800>. Package-insert content changes when the manufacturer revises the label — always screen the current insert before relying on it.